For­mer Blue­print and Pelo­ton vets team up to take on big play­ers in grow­ing hunt for a new type of small mol­e­cule

Drug dis­cov­ery is a his­tor­i­cal­ly painstak­ing process, but an­oth­er biotech has im­pressed in­vestors with its plan to make sci­en­tists’ jobs a bit eas­i­er.

Atavis­tik Bio un­cloaked on Tues­day morn­ing with a $60 mil­lion Se­ries A round led by The Col­umn Group and a new high-through­put screen­ing plat­form to iden­ti­fy al­losteric mod­u­la­tors of pro­teins. A small group of co-founders got se­ri­ous about form­ing the com­pa­ny about eight months ago. And, led by for­mer Pelo­ton CEO John Josey and for­mer Blue­print Med­i­cines CSO Mar­i­on Dorsch, the team se­cured their own lab space in Cam­bridge, MA last month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER